COGNITION THERAPEUTICS, INC.
PURCHASE, New York
Total Received
$133.4M
Total Awards
6
State
New York
Last Updated
Feb 9, 2026
Yearly Funding Trend
$128.0M24
$5.4M25
Top 6 Awards to COGNITION THERAPEUTICS, INC.
Largest individual federal awards on record for this recipient, ranked by obligated amount. Data through February 9, 2026.
| Award | Awarding Agency | Program | Place | FY | Obligation |
|---|---|---|---|---|---|
ASST_NON_R01AG065248_075 RANDOMIZED DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF CT1812 IN EARLY ALZHEIMER'S DISEASE OVER 18 MONTHS - COGNITION THERAPEUTIC… | Department of Health and Human Services National Institutes of Health | 93.866 AGING RESEARCH | PITTSBURGH, PA-12 | 2024 | $64,236,115 |
ASST_NON_R01AG058660_075 A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CT1812 IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE… | Department of Health and Human Services National Institutes of Health | 93.866 AGING RESEARCH | PITTSBURGH, PA-12 | 2024 | $30,482,877 |
ASST_NON_R01AG071643_075 A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CT1812 IN SUBJECTS WITH DEMENTIA WITH LEWY BODIES - ABSTRACT:… | Department of Health and Human Services National Institutes of Health | 93.866 AGING RESEARCH | NY-90 | 2024 | $29,498,064 |
ASST_NON_RF1AG058710_075 A PILOT ELECTROENCEPHALOGRAPHY (EEG) STUDY TO EVALUATE THE EFFECT OF CT1812 TREATMENT ON SYNAPTIC ACTIVITY IN SUBJECTS WITH MILD TO MODERATE ALZHEIMERʼS DISEASE - ABSTRACT. COGNIT… | Department of Health and Human Services National Institutes of Health | 93.866 AGING RESEARCH | PA-90 | 2025 | $5,445,051 |
ASST_NON_R42AG052249_075 OPTIMIZATION OF SIGMA-2 RECEPTOR MODULATORS FOR THE TREATMENT OF COGNITIVE DYSFUNCTION - ABSTRACT – PROJECT SUMMARY COGNITION THERAPEUTICS INC.’S (COGRX) MISSION IS TO DEVELOP EFF… | Department of Health and Human Services National Institutes of Health | 93.866 AGING RESEARCH | PITTSBURGH, PA-12 | 2024 | $2,126,690 |
ASST_NON_SB1AG073028_075 HUMAN AME STUDY OF CT1812, A SMALL MOLECULE IN PHASE 2 CLINICAL TRIALS FOR THE TREATMENT OF ALZHEIMER'S DISEASE - PROJECT SUMMARY/ABSTRACT ALZHEIMER'S DISEASE (AD) AFFLICTS NEARLY… | Department of Health and Human Services National Institutes of Health | 93.866 AGING RESEARCH | PITTSBURGH, PA-12 | 2024 | $1,642,783 |
Top 6 awards shown, ranked by obligated amount. Dates reflect performance period; last-modified dates match USAspending.gov. Complete listings include all transaction history going back to FY2024.
Funding Agencies
View All→Federal Programs (CFDA)
View All→Source: USAspending.gov · All Recipients · New York